Howard Capital Management Group LLC Purchases 92 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Howard Capital Management Group LLC raised its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 4.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,125 shares of the medical equipment provider’s stock after purchasing an additional 92 shares during the quarter. Howard Capital Management Group LLC’s holdings in Intuitive Surgical were worth $1,044,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently modified their holdings of the company. Creekmur Asset Management LLC lifted its holdings in shares of Intuitive Surgical by 200.0% in the first quarter. Creekmur Asset Management LLC now owns 63 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 42 shares in the last quarter. Ridgewood Investments LLC bought a new position in shares of Intuitive Surgical in the second quarter valued at approximately $26,000. Delos Wealth Advisors LLC lifted its holdings in shares of Intuitive Surgical by 380.0% in the first quarter. Delos Wealth Advisors LLC now owns 72 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 57 shares in the last quarter. LRI Investments LLC bought a new position in shares of Intuitive Surgical in the first quarter valued at approximately $30,000. Finally, LGT Financial Advisors LLC lifted its holdings in shares of Intuitive Surgical by 415.4% in the second quarter. LGT Financial Advisors LLC now owns 67 shares of the medical equipment provider’s stock valued at $30,000 after purchasing an additional 54 shares in the last quarter. Institutional investors own 83.64% of the company’s stock.

Insider Buying and Selling

In related news, insider Mark Brosius sold 2,115 shares of the business’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $491.91, for a total transaction of $1,040,389.65. Following the completion of the transaction, the insider now directly owns 295 shares in the company, valued at $145,113.45. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, EVP Robert Desantis sold 1,413 shares of the company’s stock in a transaction dated Friday, July 26th. The stock was sold at an average price of $438.60, for a total value of $619,741.80. Following the completion of the transaction, the executive vice president now directly owns 5,506 shares in the company, valued at approximately $2,414,931.60. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Mark Brosius sold 2,115 shares of the company’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $491.91, for a total value of $1,040,389.65. Following the completion of the transaction, the insider now owns 295 shares of the company’s stock, valued at $145,113.45. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 53,120 shares of company stock worth $25,528,753 over the last ninety days. 0.90% of the stock is owned by corporate insiders.

Intuitive Surgical Stock Performance

Shares of NASDAQ ISRG opened at $473.73 on Friday. The stock has a market cap of $168.03 billion, a PE ratio of 85.51, a price-to-earnings-growth ratio of 5.40 and a beta of 1.39. Intuitive Surgical, Inc. has a fifty-two week low of $254.85 and a fifty-two week high of $496.48. The stock has a fifty day moving average of $482.69 and a 200-day moving average of $436.91.

Intuitive Surgical (NASDAQ:ISRG) last posted its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 EPS for the quarter, topping the consensus estimate of $1.54 by $0.24. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The business had revenue of $2.01 billion during the quarter, compared to analysts’ expectations of $1.97 billion. During the same period in the previous year, the business earned $1.18 earnings per share. The firm’s revenue was up 14.5% on a year-over-year basis. On average, sell-side analysts predict that Intuitive Surgical, Inc. will post 5.22 EPS for the current year.

Analysts Set New Price Targets

ISRG has been the topic of a number of recent analyst reports. Barclays lifted their price target on Intuitive Surgical from $430.00 to $490.00 and gave the stock an “overweight” rating in a report on Thursday, July 18th. Raymond James lifted their price target on Intuitive Surgical from $500.00 to $540.00 and gave the stock an “outperform” rating in a report on Monday. Robert W. Baird lifted their price target on Intuitive Surgical from $503.00 to $565.00 and gave the stock an “outperform” rating in a report on Thursday. Evercore ISI lifted their price target on Intuitive Surgical from $410.00 to $475.00 and gave the stock an “in-line” rating in a report on Tuesday, October 1st. Finally, JPMorgan Chase & Co. lifted their price target on Intuitive Surgical from $495.00 to $575.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. Six investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $484.15.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.